Fatigue, Tumor associated
Conditions
Interventions
Group 1: Patients with histologically or cytologically diagnosted various tumor entities for which a treatment with docetaxel LIV pharmaceutical according to SPC is indicated.
Sponsors
LIV Pharma GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Histologically or cytologically diagnosted Tumors for which docetaxel LIV Pharma is approved according to SPC. - Age: over 18 years - Docetaxel LIV Pharma is used in therapy. - A hand signed and dated informed consent is available.
Exclusion criteria
Exclusion criteria: - Contraindications regarding the use of docetaxel LIV pharmaceutical according to expert information - The current therapy was started more than 12 weeks ago. - The patient is participating simultaneously part in another clinical trial. - A pregnancy is present or the patient is breastfeeding.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Course of the quality of life collected by questionnaire EORTC-C30 v 3.0 at baseline, cycle 4, 8, 12, end of treatment and follow-up examinations 1-3 | — |
Primary
| Measure | Time frame |
|---|---|
| Course of Fatigues yndroms, collected using questionnaire MFI (multidimensional fatigue inventory) at baseline, 2,4,6,8,12 cycles, end of treatment and 1 follow-up visits end of treatment and follow-up examinations 1-3 | — |
Countries
Germany
Contacts
Public ContactBurkard Heckelbacher
Datafaber GbR
Outcome results
None listed